Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy
经直肠超声检查对患者的新辅助放化疗后局部晚期直肠癌肿瘤淋巴结转移再分期的价值作者机构:Department of Radiation OncologyFirst Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of RadiotherapySun Yat-sen University Cancer CenterState Key Laboratory of Oncology in Southern ChinaGuangzhouChina Department of Endoscopy and LaserSun Yat-sen University Cancer CenterState Key Laboratory of Oncology in Southern ChinaGuangzhouChina Department of UltrasonographySun Yat-sen University Cancer CenterState Key Laboratory of Oncology in Southern ChinaGuangzhouChina
出 版 物:《Gastroenterology Report》 (胃肠病学报道(英文))
年 卷 期:2013年第1卷第3期
页 面:186-192页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:This study was supported by National Natural Science Funding of China(81071891,81172209) Guangdong Provincial Science&Technology Funding(2010B0807017,2010B031600090)
主 题:Rectal cancer neo-chemoradiotherapy(neo-CRT) transrectal ultrasonography(TRUS) TNM restaging
摘 要:Objective:To explore the value of transrectal ultrasonography(TRUS)for tumor node metastasis(TNM)restaging for patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy(neo-CRT).Methods:One hundred and forty-nine patients with locally advanced rectal cancer(cT3-4 or cN+)who underwent TRUS after neo-CRT were retrospectively *** restaging was compared with the results of post-operative pathological TNM ***:After neo-CRT,the accuracy of TRUS for diagnosing T-staging was 30.9%,with 60.4%(90/149)of cases *** sensitivity of TRUS for T-staging(T0 vs T1 vs T2 vs T3 vs T4)were 16.3%,0%,12.5%,42.6%and 75.0%,*** accuracy of TRUS for diagnosing N-staging after neo-CRT was 81.2%,with the sensitivities of N0 and N+were 93.3%and 31.0%,*** neo-CRT,27.5%(41/149)of patients achieved pathologically complete response(pCR).The sensitivity,specificity,positive predictive value and negative predictive values of TRUS for pCR were 17.1%,99.1%,87.5%and 75.9%,***:TRUS can be applied for restaging T4 and N0,and has potential for screening out patients with pCR in those with locally advanced rectal cancer after neo-CRT,although some stages are overestimated for T-staging and its sensitivity for predicting pCR is low.